FDA issues warning over-the-counter diarrhea drug

September 18, 2012

(AP)—The Food and Drug Administration is warning consumers not to use an over-the-counter drug called Intestinomicina because the anti-diarrhea treatment contains a drug linked to life-threatening injuries.

The El Salvador-manufactured drug comes in pills and liquid forms and is sold as a treatment for at international grocery stores and specialty stores in the U.S.

Regulators say Intestinomicina contains the drug chloramphenicol, which can interfere with the production of red and . People with anemia and other low blood cell counts are at greater risk of injury or death from using the drug.

The FDA recalled all oral forms of chloramphenicol in July due to safety risks. The agency is asking consumers who purchased the product to stop taking it and consult a health care professional.

Explore further: US warns of drugs in Reumofan dietary supplements

shares

Related Stories

US warns of drugs in Reumofan dietary supplements

August 21, 2012
(AP) — The U.S. Food and Drug Administration is warning consumers not to use Reumofan dietary supplements, after receiving reports of bleeding, stroke and death among Americans taking the Mexico-manufactured pills.

Platelet drug shows clinical benefits for severe, unresponsive aplastic anemia

July 4, 2012
Eltrombopag, a drug that was designed to stimulate production of platelets from the bone marrow and thereby improve blood clotting, can raise blood cell levels in some people with severe aplastic anemia who have failed all ...

Perjeta approved for advanced breast cancer

June 11, 2012
(HealthDay) -- Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat people with HER2-positive late-stage breast cancer, the agency said in a news release.

Omontys approved for anemic people with kidney disease

March 27, 2012
(HealthDay) -- Omontys (peginesatide) has been approved by the U.S. Food and Drug Administration to treat anemia in adults who require dialysis due to chronic kidney disease.

Aubagio approved for multiple sclerosis

September 13, 2012
(HealthDay)—Aubagio (teriflunomide) has been approved by the U.S. Food and Drug Administration to treat adults with relapsing forms of multiple sclerosis (MS).

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.